

بسم الله الرحمن الرحيم

 $\infty\infty\infty$

تم رفع هذه الرسالة بواسطة / حسام الدين محمد مغربي

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى مسئولية عن محتوى هذه الرسالة.

AIN SHAMS UNIVERSITY

Since 1992

Propries 1992

ملاحظات: لا يوجد

Serum Soluble CD163 as a Marker of activity in MS Patients

Thesis

Submitted for partial fulfillment of master degree in Clinical Pathology

By

Eman Ahmed Metwally Hassan

MB, Bch, Ain shams University

Under supervision of

Prof. Dr. Mona Mohamed Rafik

Professor of Clinical Pathology Faculty of Medicine, Ain Shams University

Prof. Dr. Dina Ahmed Soliman

Professor of Clinical Pathology Faculty of Medicine, Ain Shams University

Dr. Marwa Rushdy El Najjar

Assistant professor of Clinical Pathology Faculty of Medicine, Ain Shams University

Dr. Alaa Mohamed Abostate

Lecturer of Neurology
Faculty of Medicine, Ain Shams University

Faculty of Medicine Ain Shams University 2022



سورة البقرة الآية: ٣٢

Acknowledgment

First and foremost, I feel always indebted to **Allah**, the Most Kind and Most Merciful.

I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Mona Mohamed Rafik,** Professor of Clinical Pathology - Faculty of Medicine- Ain Shams University for her keen guidance, kind supervision, valuable advice, instructions and continuous encouragement, which made possible the completion of this work.

I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Dina Ahmed Soliman**, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her guidance, active participation and constant help throughout this work.

I am deeply thankful to **Dr. Marwa Rushdy El Majjar**, Assistant professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her great help, cooperation and guidance.

I wish to introduce my deep respect and thanks to **Dr. Alaa Mohamed Abostate**, Lecturer of Neurology, Faculty of Medicine, Ain Shams University, for her kindness, supervision and cooperation in this work.

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Eman Ahmed Metwally Hassan

Serum Soluble CD163 as a Marker of Activity in MS patients

Authors:

 Professor Mona Mohamed Rafik - Professor of Clinical Pathology - Ain Shams University.

Monarafik@hotmail.com

 Professor Dina Ahmed Soliman - Professor of Clinical Pathology - Ain Shams University.

<u>Dinasoliman75@yahoo.com</u>

 Associate professor Marwa Rushdy El Najjar -Associate professor of Clinical Pathology - Ain Shams University.

marwarushdy@med.asu.edu.eg

 Doctor Alaa Mohamed Abostate - Lecturer of Neurology - Ain Shams University.

Dr.alaaabousteit@outlook.com

Corresponding author: Eman Ahmed Metwally Hassan, resident in the Clinical Pathology department, Nasr City Hospital for Health Insurance, Cairo, Egypt, postal code: 11835.

Email: Emanahmed14890@gmail.com.

phone number: (+2)01111516052.

Serum Soluble CD163 as a Marker of Activity in MS patients

Rafik M.¹, Soliman D.¹, Rushdy M.¹, Abostate A.², Metwally E.³.

¹Department of Clinical Pathology and Immunology, Ain Shams University.

²Department of Neurology, Ain Shams University.

3Resident in the Clinical Pathology department, Nasr City Hospital for Health Insurance, Cairo, Egypt.

Abstract

Background: Multiple sclerosis (MS) is chronic autoimmune disease that affects the central nervous system. Microglia and macrophages have a substantial role in myelin and axonal degeneration by causing neuro-inflammatory damage. Soluble CD163 one of the myeloid linage biomarkers, showed a better correlation with monocyte count in the CSF of patients. **Objective:** In the current case MS control observational study, we aimed to assess serum level of sCD163 as an immunological non-invasive marker for MS activity. Patients and methods: Sixty relapsing remitting multiple sclerosis (RRMS) patients were included and divided into 2 groups based on disease activity. Twenty-eight matched healthy controls were included and all subjects' serum levels of sCD163 were measured using ELISA. Results: We demonstrated a highly significant difference between the whole patients compared to controls with a concomitant no statistically

significant difference between the patients' groups. **In conclusion:** We emphasized the relevance of serum level of sCD163 as a non-invasive immunological biomarker in the diagnostic panel of MS reflecting the inflammatory process rather than the activity status of the patients.

Key words: Multiple sclerosis, sCD163, RRMS.

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations	iii
Introduction	1
Aim of the Work	3
Review of Literature	
Multiple Sclerosis	4
CD163 and Its Clinical Significance	29
Subjects and Methods	41
Results	50
Discussion	59
Summary and Conclusion	66
References	68
Arabic Summary	1

List of Tables

Table No.	Title	Page No.
Table 1:	Predictors of good and poor prognosis in	MS7
Table 2:	Reagent and material provided:	43
Table 3:	Descriptive data of all subjects a demographic, laboratory and clinical para	_
Table 4:	Statistical analysis of the cases groups (as regard demographic, laboratory and parameters.	d clinical
Table 5:	Comparative analysis between the studie as regard the serum level of sCD163	
Table 6:	Statistical correlation between serum sCD163 and age, EDSS, duration of the and number of relapses during last year patient's group.	e disease ar among
Table 7:	Statistical relation between serum level of MRI finding, CSF-OCB and current DM patient's group	Ds in the
Table 8:	ROC curve analysis between patients and	controls58

List of Figures

Figure No.	Title Page	e No.
Figure 1:	Different types of MS according to clinical course	6
Figure 2:	Sequences of the BBB breakdown – T cell-mediated immune response	1
Figure 3:	Role of Th17 cell in pathogenesis of MS	
Figure 4:	Role of B cells in pathogenesis of multiple sclerosis.	22
Figure 5:	The effector functions of neutrophils that are involved in the pathogenesis of MS	
Figure 6:	Structure of CD163.	
Figure 7:	Shedding of sCD163	31
Figure 8:	Macrophages and microglia and the possible roles of sCD163, NEO, NfL, CXCL13, OPN, and IgG in pathology of MS	1
Figure 9:	Serial dilutions of the standard working solution	
Figure 10:	Standard curve plotted on log-log graph of optical density against human sCD163 concentration	1
Figure 11:	Box and whisker graph of serum level of sCD163 in the three groups.	ı
Figure 12:	ROC curve for serum level of sCD163 between patients and controls	1

List of Abbreviations

Full term **Abbreviations** Ab: Antibody ADAM: A disintegrin and metalloproteinase Ag: Antigen APCs: Antigen presenting cells AUC: Area under curve BBB: Blood brain barrier BCR B cell receptor CAMs: Cell adhesion molecules CCL: CC chemokine ligand CCR:CC chemokine receptor CD:Cluster of Differentiation cDCs:Conventional dendritic cells CIS:Clinically isolated syndrome CNS: Central nervous system COVID-19: Corona virus disease 2019 CSF: Cerebrospinal fluid CXCL: C-X-C motif ligand DCs: Dendritic cells DMTs: Disease-modifying therapies DNA: Deoxyribonucleic acid EAE: Experimental autoimmune encephalomyelitis EBNA-1: Epstein Barr nuclear antigen A-1 EBV: Epstein Barr Virus EC: Epithelial cell Ecto-CD163: Ectodomain CD163 EDSS: Expanded Disability Status Scale ELISA: Enzyme linked immunosorbent assay EV-CD163: Extracellular vesicles CD163 FasL: Fas ligand FoxP3:Fork head box P3 GM-CSF: Granulocyte-macrophage colony stimulating factor

List of Abbreviations (Cont...)

Abbreviations

Full term

GWASs:	. Genome-wide association studies
Hb:	.Hemoglobin
HBV:	. Hepatitis B virus
	. Hepatocellular carcinoma
HCV:	. Hepatitis C virus
HIV:	. Human immunodeficiency virus
HLA:	. Human leukocyte antigen
HRP:	. Horseradish Peroxidase
HS:	. Highly significant
ICAM-1:	. Intercellular adhesion molecule 1
ICU:	. Intensive care unit
IFN:	. Interferon
IFNβ:	. Interferon beta
Ig:	. Immunoglobulin
IL:	. Interleukin
IM:	. Intramuscular
IQR:	. Inter-quartile range
iTreg:	. Inducible T regulatory
IV:	. Intravenous
LPS:	. Lipopolysaccharide
MBP:	. Myelin basic protein
mCD163:	. Membrane CD163
M-CSF:	. Macrophage-colony stimulating factor
MHC:	. Major histocompatibility complex
MMPs:	. Matrix metalloproteinases
mo-DCs:	. Monocyte-derived dendritic cells
MOG:	. Myelin oligodendrocyte glycoprotein
MPO:	. Myeloperoxidase
MRI:	. Magnetic resonance imaging
MS:	. Multiple sclerosis
NA:	. Not available

List of Abbreviations (Cont...)

Abbreviations Full term NAFLD:Non-alcoholic fatty liver disease NASH:Non-alcoholic steatohepatitis NE:Neutrophil elastase NEO:Neopterin NETs: Neutrophil Extracellular Traps NfL:Neurofilament light polypeptide NK:Natural killer NMSS:National Multiple Sclerosis Society NPV:Negative predictive value Nrf2:Nuclear factor (erythroid-derived 2)-like 2 NS:Non-significant nTreg: Natural T regulatory nVDR: Nuclear vitamin D receptor OCBs:Oligoclonal bands OD: Optical density OPN: Osteopontin pDCs:Plasmacytoid dendritic cells PLP: Proteolipid protein PMA: Phorbol 12-myristate13-acetate PPMS: Primary-progressive MS PPV: Positive predictive value PRMS: Progressive- relapsing MS RA: Rheumatoid arthritis ROC: Receiver operating characteristic curve RORyt: Retinoic acid related orphan receptor ROS: Reactive oxygen species RRMS: Relapsing-remitting MS S: Significant s:Soluble SC:Schwann cell

SC: Subcutaneous

List of Abbreviations (Cont...)

Abbreviations	Full term
sCD14:	. Soluble CD14
sCD163:	. Soluble CD163
sCD206:	. Soluble CD206
SD:	. Standard deviation
SLE:	. Systemic lupus erythematosus
SPMS:	. Secondary-progressive MS
SPSS:	. Statistical Package for Social Science
SRCR:	. Scavenger receptor cysteine rich
TACE:	. Tumor necrosis factor (TNF) converting enzyme
TCR:	. T cell receptors
TGF-β:	. Transforming growth factor beta
Th:	. T helper
TMB:	. Tetramethyl benzidine
TNF:	. Tumor necrosis factor
Treg:	. T regulatory
TWEAK:	. Tumor necrosis factor (TNF)-like weak inducer of
	apoptosis
VCAM:	. Vascular cell adhesion molecules
VLA-4:	. Very late antigen 4

Introduction

Multiple sclerosis (MS) is considered as a chronic autoimmune-mediated demyelinating disease that affects the central nervous system (CNS) (*Bjornevik et al.*, 2022) which is usually associated with different degrees of progressive disabilities (*Mahad et al.*, 2015). Diagnosis of MS depends mainly on clinical picture, magnetic resonance imaging (MRI) findings and cerebrospinal fluid (CSF) oligoclonal bands (OCBs) (*Lo Sasso et al.*, 2019).

Microglia and macrophages are the dominant immune cell type that are involved in MS lesions as they interact with adaptive immune cells to initiate demyelination and play role in both destruction and repair (*Kamma et al., 2022*). Activated macrophages are derived from peripheral monocytes and secrete proinflammatory cytokines that mediate demyelination and axonal damage, on the other hand, activated resident microglia clear cellular debris and thus promote tissue recovery (*Harris et al., 2017*).

Biomarkers of myeloid lineage, such as soluble cluster of differentiation 163 (sCD163) and soluble CD14 (sCD14), were found to be elevated in the CSF of MS patient (*Komori et al.*, 2015). Soluble CD163 showed a better correlation with monocyte count in MS CSF, and previous studies have suggested that it may be a biomarker of macrophage activity (*Harris et al.*, 2017).